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Abstract 
 
The Wistar Kyoto rat (WKY) and the Spontaneously Hypertensive Rat (SHR) inbred 
strains are well-established models for human crescentic glomerulonephritis (CRGN) 
and metabolic syndrome respectively. Novel transgenic (Tg) strains add research 
opportunities and increase scientific value to well-established rat models. We have 
created two novel Tg strains using Sleeping Beauty transposon germline 
transgenesis, ubiquitously expressing green fluorescent protein (GFP) under the rat 
elongation factor 1 alpha (rEF1a) promoter on the WKY and SHR genetic 
backgrounds. The Sleeping Beauty system functioned with high transgenesis 
efficiency in our hands: 75% of the new rats born after embryo microinjections were 
transgene positive. By ligation-mediated PCR, we located the genome integration 
sites, confirming no exonic disruption and defining single or low copy number of the 
transgenes in the new WKY-GFP and SHR-GFP Tg lines. We report GFP bright 
expression in embryos, tissues and organs in both lines and show preliminary in vitro 
and in vivo imaging data that show the utility of the new GFP-expressing lines for 
adoptive transfer, transplantation and fate mapping studies of CRGN, metabolic 
syndrome and other traits for which these strains have been extensively studied over 
the past four decades.  
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Introduction 
The rat has long been an important physiological model of complex human disease 
(Aitman et al., 2008; Iannaccone and Jacob, 2009). Two well-studied strains, both 
originating from Wistar stock, are the Wistar Kyoto (WKY) and Spontaneously 
Hypertensive (SHR) inbred rats (Kurtz and Morris, 1987; Okamoto and Aoki, 1963).  
The Wistar Kyoto (WKY) rat has been studied extensively as a model of crescentic 
glomerulonephritis (Aitman et al., 2006; Atanur et al., 2013; Behmoaras et al., 2008; 
Behmoaras et al., 2015; D'Souza et al., 2013; Kanno et al., 1998; Sado et al., 1984; 
Smith et al., 2007), as a control for the SHR strain and as a model of depression and 
behavioural abnormalities (Will et al., 2003). The SHR strain has been widely used 
as a model of the human hypertension and metabolic syndrome as well as a large 
number of other pathophysiological phenotypes including, cardiac hypertrophy and 
failure, insulin resistance and defects in lipid metabolism (Aitman et al., 1999; Aitman 
et al., 1997; Lepretre et al., 2004; Pravenec et al., 2008; Yamori and Okamoto, 
1974).  
 
Both inbred strains are well characterised, with 199 and 197 quantitative trait loci 
(QTLs) mapped respectively in WKY and SHR (Shimoyama et al., 2015), and whole 
genome sequences of both strains now publically available (Aitman et al., 2008; 
Atanur et al., 2010; Atanur et al., 2013; Hubner et al., 2005; Shimoyama et al., 
2015). With the advent of gene targeting technologies that are suited to use in rats, 
including Zinc Finger Nucleases (ZFNs) (Geurts et al., 2009), Transcription activator-
like effector nucleases (TALENs) (Tesson et al., 2011), Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPRs) (Shen et al., 2013) and Sleeping 
Beauty (SB) transposon system (Ivics et al., 2009; Kitada et al., 2007; Mates, 2011), 
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increasing numbers of new transgenic (Tg), knockout and knock-in rat models have 
been created to elucidate the functional basis of disease phenotypes (Jacob et al., 
2010)  
 
Fluorescent imaging for in vitro and in vivo analysis of biological processes 
combined with GFP Tg models are valuable reagents for translational research. Tg 
models reporting ubiquitous enhanced green fluorescent protein (GFP) have been 
described in inbred rats mostly under the control of the chimeric CAG 
(cytomegalovirus enhancer, chicken β-actin enhancer-promoter, and intronic 
sequences from rabbit β –globin) promoter, using classical transgenesis (Hakamata 
et al., 2001), lentivirus integrations (Michalkiewicz et al., 2007) and Sleeping Beauty 
(Katter et al., 2013). However, there are shortcomings in some of these approaches. 
Classical transgenesis (Charreau et al., 1996; Mullins et al., 1990) has low efficiency 
and is likely to insert concatemer transgene copies in the genome. This can 
predispose to gene silencing and a high frequency of mosaic founders (Bishop and 
Smith, 1989; Garrick et al., 1998; Whitelaw et al., 1993). Lentivirus integrations have 
high efficiency, but also have drawbacks including triggering of transgene silencing 
by epigenetic regulation and production of mosaic founders. As well as limitations in 
transgene size, lentiviruses can cause embryo toxicity due to preferential transgene 
insertion in endogenous genes (Ellis, 2005; Hofmann et al., 2006; Lois et al., 2002; 
Wolf and Goff, 2009).  
 
This paper describes the creation of two new ubiquitously expressing GFP models in 
WKY and SHR inbred rat lines by combining a highly efficient transgenic system and 
a strong mammalian endogenous promoter. We took advantage of the Sleeping 
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Beauty (SB) transposon system that randomly integrates single copies or low copy 
number of a gene of interest (Ivics et al., 2014; Mates, 2011). We opted for the rat 
Elongation Factor 1 alpha (rEF1a) promoter (Kim et al., 1990; Mizushima and 
Nagata, 1990). The rEF1a gene encodes an isoform of the alpha subunit of the 
elongation factor-1 complex, which is responsible for the enzymatic delivery of 
aminoacyl tRNAs to the ribosome (Sasikumar et al., 2012) and its promoter has 
been successfully used in gene therapy studies as a non-viral alternative to the 
cytomegalovirus promoter (Gill et al., 2001; Serafini et al., 2004; Zheng and Baum, 
2005). We report GFP expression in embryos, tissues, ex vivo cell cultures and in an 
in vivo imaging model of bone marrow transplantation to validate these lines as 
useful tools for translational research. 
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Materials and methods 
All animals were housed in individually ventilated cages. All procedures were carried 
out according to the institutional guidelines for the care and use of experimental 
animals and the ARRIVE guidelines.  Animal studies were approved by the UK 
Home Office. 
 
Generation of ubiquitous GFP WKY and SHR rats using Sleeping Beauty 
transgenesis.  
Preparation of the Transposon donor plasmid and microinjection: Schematic of 
plasmid is shown in Figure 1A. The CAGGS promoter in pSB IR-DR(L)-CAGGS-
eGFP-pA-IR-DR(R) plasmid was replaced with the native rat Elongation Factor-1 
alpha promoter (rEF1a) from pDRIVE-rEF1α (InvivoGen). Fragment PstI-NcoI 
containing rEF1a was blunted and inserted into the NotI-MluI blunted backbone. 
Screening for “sense” orientation was by EcoRI digestion. Functional elements of 
sleeping beauty construct were confirmed by sequencing. The SB100x transposase 
was prepared following protocol by Mates et al (Mates, 2011).  
Synchronization of oestrus cycle in rat recipients: The foster females aged 8 to 12 
weeks were injected intraperitoneally (i.p) with 40ug of luteinizing hormone-releasing 
hormone (LH-RH) agonist 4 days prior to mating. On the day of mating, the 
recipients were individually placed with vasectomised males. The following day, the 
females were de-mated and examined for the presence of copulation plug. The 
females presenting a plug were used as embryo recipient for embryo transfer 
surgery on the same day.  
Embryo preparation and microinjection: 6 SHR and 9 WKY females aged 4 to 6 
weeks old were used as embryos donors. 2 days prior to mating, females were 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
injected i.p with 30 IU of pregnant mares serum gonadotropin (PMSG).  On the day 
of mating, the females were injected i.p with 40 IU of human pregnancy urine 
chorionic gonadotropin (HCG) and placed individually with SHR or WKY males. The 
following day, the females were separated, culled and the oviducts removed. The 
oviducts were then placed in M2 media (Sigma) and the ampulla torn to release 
single cell embryos. Hyaluronidase was then added to the media to remove the 
cumulus cells. The embryos were collected and cleaned using a mouth pipette. The 
fertilized embryos were transferred from M2 to KSOMaa media (Zenith biotech) and 
left in the incubator at 37°C, 5% CO2 until they were used for pro nuclear injections 
and embryo transfer (20-40 embryos per female) using standard protocols (Filipiak 
and Saunders, 2006; Geurts et al., 2009). Briefly, pronuclear injection of mixed donor 
plasmid (0.4 ng/ul) and mRNA SB100X transposase (5 ng/ul) was performed in WKY 
and SHR rat one cell embryos.  Injected embryos were transferred to the oviduct of 
day-0.5 pseudopregnant rats and then replaced into Sprague Dawley rat recipients 
by embryo transfer surgery. 
 
Screening of GFP positive pups. 
Selected F0 founders were crossed with wild types and F1 were screened by PCR 
and GFP-positive animals were further screened for GFP expression in blood to 
choose high expressers for breeding.  Genomic DNA was extracted from ear clips by 
overnight proteinase K digestion at 56°C and precipitated next day with isopropanol. 
PCR with two primer pairs was performed to detect 343bp Actin fragment as control 
and 180bp fragment as transgene positive. 
DNA_rat_bActin_F: 5’-TGTGTTGTCCCTGTATGCCTCT-3’ 
DNA_rat_bActin_R: 5’- ATTGCCGATAGTGATGACCTGA-3’  
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
GFP_F: 5’- GGCACCTACCCCAGCGGCTA-3’ 
GFP_R: 5’-CCGGTGCCCACCACCTTGAA-3’ 
PCR cycle conditions were: 95°C for 2 min, 30 cycles of 95°C for 30 sec, 60°C for 30 
sec, and 72°C for 30 sec with a final 5 min elongation at 72°C. Tail blood was 
collected into lithium-heparin microvette tubes and GFP blood expression was 
assessed using an AccuriC6 (BD) flow cytometer (see ‘detection of GFP expression’ 
below). Whole animal GFP expression was confirmed under an excitation light 
(489nm) (Fig. 1B). 
 
Integration sites identification and locus confirmation 
Ligation-mediated PCR (LMPCR) (Ivics et al., 2014) was used to locate the 
transgene integration site in the host genome. We designed primers to combine with 
Tbal 5’-CTTGTGTCATGCACAAAGTAGATGTCC-3’ from the LMPCR protocol to 
verify individual transgene integration by locus-specific PCR:  
Ch1_is_F: 5’-GACACATCCCTTGCTGTGGA-3’  
Ch1_is_R: 5’-GCTATAACAAAGGGGACAGGCT-3’;  
Ch5_is_F: 5’-CTCCAGCTTGCTTCTTGGGA-3’  
Ch5_is_R: 5’-ACTGCACCCCAGAAAAAGCA-3’;  
Ch8_is_F: 5’-GAAACACTGCACGTGGTGAC-3’  
Ch8_is_R: 5’-TCTCTTCCCACAGCCTTTCC-3’ 
 
Detection of GFP expression 
Embryos: E4.5 embryos were collected and carefully placed in glass bottom petri 
dishes for confocal imaging, using Leica Sp5 microscope. For some embryos, E4.5 
were harvested and cultured overnight (12hrs) in M2 media before imaging. 
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Organs: Brain, eye, salivary gland, thymus, heart, lung, liver, kidney, adrenal gland 
gut, pancreas, spleen, and quadraceps were dissected, washed, fixed (4% PFA 
30mins) and mounted on open glass slides for imaging using a Leica MZ16F 
fluorescence stereoscope and Leica camera DFC420C. For some organs, 
longitudinal dissection was used to show GFP intensity of inner organ structures. In 
addition, kidney, liver, spleen and thymus gross dissections were embedded in OCT 
and 2μm frozen sections mounted onto slides using hard set mounting media with 
DAPI (vectashield). Sections were imaged using upright fluorescent microscope 
(Olympus) for GFP and DAPI. 
Blood: Blood was collected into lithium-heparin microvette tubes from tail bleeds. 
Red blood cells were lysed (155mM NH4Cl, 12mM NaHCO3, 100mM EDTA) and 
leukocytes washed in PBS before permeabilisation (fix-Perm kit, Invitrogen) and 
incubation with antibodies against rat Gran-PE (HIS48), MHC-II-perCP (HIS19) and 
CD68-alexa700 (ED1) (all 1:50; Biologend). Cells were analysed by flow cytometry 
using an AccuriC6 (BD) with appropriate colour compensation and gates set to 
unstained cells. 
 
Culture of bone marrow-derived macrophages 
Rat bone marrow-derived macrophages were isolated from femurs and differentiated 
using RPMI 1640 supplemented with 10% Fetal Bovine Serum (Hyclone) and 5 
ng/ml Rat M-CSF (Peprotech) as previously described (D'Souza et al., 2013). Cells 
were cultured in 12 well plates for 5 or 10 days and GFP fluorescence images were 
taken using confocal microscopy. 
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Intravital microscopy 
To examine utility of GFP Tg rats for translational work, we tested the real-time 
imaging of kidney leukocyte-endothelial interactions using intravital microscopy in 
WKY-GFP bone marrow chimeras. WKY-GFP bone marrow was harvested and 
injected into WKY wild type recipient to create bone marrow chimeras as previously 
described (Smith et al., 2007). Briefly, femurs were harvested from WKY-GFP rats 
and bone marrow cells collected under sterile conditions. Recipient WKY rats were 
irradiated (8Gy) and bone marrow cells (approx. 8x106) injected intravenously (i.v). 
After 8 weeks, reconstitution was confirmed (data not shown) and kidney imaged 
under anaesthesia, after exposure of superficial kidney cortex from surrounding 
tissue by careful blunt dissection. Images were taken using SP5 confocal 
microscope with i.v infusion of 70kDa- dextran tetramethylrhodamine (Invitrogen). 
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Results 
Microinjection results 
Seventy-five percent of newborn pups after microinjections were GFP positive by 
direct inspection under UV light and by PCR. PCR assay results corresponded 
exactly to GFP expression by direct inspection in both WKY-GFP and SHR-GFP rat 
lines (Table 1).  
Two positive F0 founders from each strain were crossed to wild type to confirm 
transgene germline transmission. All F0 founders transmitted the transgene. Only 
one high GFP expresser F0 per strain was used to derive each transgenic (Tg) rat 
line. Both lines showed normal growth, were able to reproduce, germline transmit the 
transgene and after more than five generations, GFP expression was maintained 
without any sign of transgene silencing. 
 
Examination of the GFP Integration site 
Ligation-mediated PCR (LMPCR) protocol (Ivics et al., 2014) was used to locate the 
transgene integration site in the host genome. GFP transgene insertion sites were 
located using Ensembl genome browser, Rat (Rnor_6.0).  
Two integration sites were identified in the WKY-GFP founder of the Tg line on 
Chromosome 8:28170658 and Chromosome 1:276465837, both located in intronic 
gene areas, Jam3 (ENSRNOG00000009149) intron 1 and Vti1a 
(ENSRNOG00000042786) intron 6 respectively (Fig. 1C). The Jam3 intron 1 is 
51319bp long, and the transgene resides at 37.8kb from exon 1 and 13.5kb from 
exon 2. In Vti1a intron 6, 102565 bp long, the transgene is located at 81.4kb from 
exon 5 and 21.1kb from exon 6. 
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One single location was identified in the SHR-GFP founder of the Tg line on 
Chromosome 5:108698150, an intergenic area where the closest gene, Zfp353 
(ENSRNOG00000050804) is located at 47.9kb downstream (Fig. 1C). 
GFP expression in embryos, tissues and blood 
To examine the level of GFP expression in tissues from Tg WKY and SHR rats; 
blood, cells and organs were processed for fluorescence microscopy. Figure 2 
shows representative examples of GFP expression in E4.5 early blastocyst embryos 
from homozygote WKY-GFP female crossed with wild type WKY male.  All embryos 
were GFP bright which sustained for at least 12hrs in culture (Fig. 2, lower panel). 
Similar expression was noted in WKY-GFP homozygotes and SHR-GFP rats (data 
not shown). 
 
We next isolated brain, eye, salivary glands, thymus, heart, lung, liver, kidney, 
adrenal glands, gut, pancreas, spleen, and quadraceps from wildtype (SHR), WKY-
GFP and SHR-GFP rats. All organs displayed bright GFP expression with some 
differences in GFP intensity between and within organs (Fig. 3 and Fig. S1). In 
general GFP intensity was moderately less in SHR rats, although both strains 
expressed GFP in all organs and tissues investigated (Fig. 3). Interestingly, small 
variations in GFP expression were observed in heart, kidney, thymus and brain 
tissue, localised to specific areas within the organs (Fig. 3). This may reflect 
differences in rEF1a expression in different cell types.  
 
GFP intensity was also maintained after tissue histological processing. Kidney, liver, 
spleen and thymus were processed for frozen sectioning and stained for GFP and 
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DAPI expression. All tissues were GFP bright, with some differences in GFP 
expression across the tissue (Fig. S2). 
 
We next analysed GFP expression in blood cell populations using flow cytometry. All 
blood leukocyte populations, based on either SSChigh or SSClow cells expressed 
similar amounts of GFP intensity in both WKY-GFP and SHR-GFP rats (Fig. 4A). 
However, after gating for either granulocytes (Gran), MHC-II or CD68 there was 
noticeable differences in GFP expression on some subpopulations in SHR-GFP rats 
(Fig. 4B). Similar data was noted for WKY-GFP rats (data not shown). 
CD68negGranposMHC-IIhigh cells, which are most likely lymphocyte and some 
granulocyte populations, expressed the highest level of GFP (Fig. 4B), whereas 
CD68pos (monocytes) are GFP intermediate and GFPlow expressing cells are within 
Granpos and MHC-IIhigh populations (Fig. 4B). The differences may reflect rEF1a 
expression in different circulating subpopulations.  
 
Bone marrow derived macrophage culture in-vitro 
To examine if GFP could be sustained in primary cell culture passage, which would 
be useful for downstream experimental applications, we examined GFP expression 
in bone marrow-derived macrophages (BMDM). BMDMs cultured over 5 and 10 days 
sustained high GFP expression, as detected by fluorescence microscopy (Fig. 5A). 
There was no difference in WKY-GFP or SHR-GFP BMDM GFP expression and 
similar amounts of GFP were expressed between 5 and 10 days (Fig. 5A). This 
indicates that within proliferating macrophage cultures, rEF1a activity and 
consequently GFP intensity is maintained in daughter cells. 
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In-vivo bone marrow chimeras and intravital microscopy 
To further examine the utility of Tg rat GFP lines in potential disease models and in 
vivo applications, we examined GFP intensity in WKY-GFP bone marrow chimera 
experiments using intravital microscopy. WKY-GFP BMT was performed in WKY 
recipients and the kidney cortex exposed for confocal imaging. Figure 5B shows that 
GFP bright cells can be seen located at the endothelial interface. 
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Discussion 
 
The potential of rat models for understanding basic biology and human health and 
disease (Aitman et al., 2008) has increased owing to availability of new gene 
targeting tools applicable to the rat (Atanur et al., 2013; Jacob et al., 2010) and 
communal efforts to increase and refine rat genomic resources. Important aims of 
creating Tg rat models, or any Tg animal model, are to achieve high transgenesis 
efficiency with strong and permanent expression of the gene of interest through 
generations, with high efficiency to minimise use of resources and animal numbers. 
The efficiency of transgenesis has increased in recent years due to development and 
refinement of new systems, from low efficiency of classical transgenesis by 
microinjection of naked DNA (Charreau et al., 1996; Filipiak and Saunders, 2006) to 
higher efficiency with retroviral transgenesis and the latest lentivirus vectors 
(Michalkiewicz et al., 2007). The Sleeping Beauty transposon system has 
advantages for germline transgenesis as a simpler and safer delivery system, 
matching or exceeding other approaches. This approach with a single copy of a 
permanent insertion in the genome leads to preferential intergenic integrations, and 
is less prone to silencing (Ivics et al., 2014; Katter et al., 2013; Mates, 2011; Mates 
et al., 2009; Park, 2007).  
 
We have created two new transgenic lines, on the WKY and SHR genetic 
backgrounds, that display and take advantage of many of these characteristics. In 
our experiments, 75% of new F0 born pups were transgene positive (Table 1), one of 
the highest transgenesis efficiencies reported. Such efficiency, in our case, seems 
independent of the SHR or WKY genetic rat background. In our Tg models, GFP 
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expression appeared to be independent of integration site and genomic background 
and dependant of promoter endogenous/native activity. Further, expression was 
transmitted unchanged through more than five generations of breeding and through 
5-10 days of in vitro macrophage culture, demonstrating the stability of expression 
from the transgene constructs integrated into the germline genome. Finally, the high 
level of GFP expression was shown to have created a suitable platform for cell fate 
tracking through intravital microscopy and confocal imaging.  
 
Avoiding the production of mosaic founders is an important way to minimise cost, 
and increasing effective functional efficiency.  Sleeping beauty is a plasmid/mRNA 
based method where the transposase mRNA does not need embryonic genome 
activation.  In rats this begins at the 4-cell stage and only needs translation of the 
transposase mRNA in the early embryo stages.  This system largely avoids the 
creation of mosaic founders (Mates, 2011). This is superior to lentivirus transgenesis 
where reverse transcription is necessary and where viral infection and integration 
can continue with embryonic development (Park, 2007). The transmission of the 
transgene over 5 generations in our lines excludes the possibility of mosaicism in the 
selected founders of our established WKY and SHR lines. 
 
The Sleeping Beauty transposon system randomly integrates the gene of interest in 
the genome with a bias to intergenic integration (Ammar et al., 2012; Grabundzija et 
al., 2010; Katter et al., 2013; Moldt et al., 2011). We show in our new GFP Tg rat 
models, by locating and verifying the integration locus sites, that there was no 
functional gene disruption due to exon insertion. We confirmed individual transgene 
integration by locus-specific PCR, making possible the isolation of each integration, 
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by selecting breeding and establishing unique locus integration per rat line. In the 
SHR inbred background the insertion position was at Chromosome 5:108698150, an 
intergenic locus 47.9kb upstream of gene Zfp353. In such a location, using the rat 
genome information available (Rnor_6.0), we cannot foresee any biological 
impairment. In the WKY inbred background the two located integration sites were 
intronic, one on Chromosome 1:276465837, intron 6 (102,565bp long) of gene Vti1a 
(Vesicle transport through interaction with t-SNAREs 1A) and the other on 
Chromosome 8:28170658, intron 1 (51319bp) of gene Jam3 (Junctional adhesion 
molecule 3). Regulatory splicing elements can be found in the intron up to 300bp 
from the exon-intron border (Barash et al., 2010). Our intronic integrations are far 
away from these areas, being ~13.5kb from the closest exon-intron border. 
Therefore effects on the splicing machinery would not be foreseen although 
interference due to Tg insertion in introns, which regulate gene expression by 
noncoding RNA molecules, intron-mediated enhancement or by other intronic 
regulatory functions, cannot be completely excluded.  
 
To ensure strong and permanent expression, many factors are necessary, including 
a strong promoter and fortuitous integration in the genome to avoid transgene 
silencing (Kioussis and Festenstein, 1997). The selection of promoter was 
fundamental to accomplish this goal. We decided to move away from the most used, 
the chimeric exogenous CAG promoter because it contains the cytomegalovirus 
enhancer sequence and due to its viral nature could trigger silencing mechanisms 
affecting GFP expression.  Moreover, although CAG promoters are ubiquitous, it has 
been reported there are different expression patterns within different tissues and 
within different transgenic models, from high expression to low or no expression 
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(Hakamata et al., 2001; Inoue et al., 2005; Katter et al., 2013; Michalkiewicz et al., 
2007; Murakami and Kobayashi, 2012; Popova et al., 2008; Takeuchi et al., 2003). 
We therefore opted for an endogenous promoter to maximise the likelihood of 
permanent expression and escape from gene silencing. Most promoters that have 
been used have some disadvantages. For example rat transgenic models using 
Ubiquitin C (van den Brandt et al., 2004) , phosphoglycerate kinase 1 (PGK1) (Remy 
et al., 2010) and Rosa26 (Montanari et al., 2014) promoters report chimeric 
expression.  Potential promoter candidates were compared using the on-line BioGPS 
application (http://biogps.org) where the tissue-specific pattern of mRNA expression 
of their endogenous driven protein is quantified. We hypothesized that the 
expression of GFP will mimic our gene of interest, at least to an extent, to the 
reported expression. Eukaryotic Elongation factor 1 alpha 1 (EEF1A1) or rat 
Elongation factor 1 alpha (rEF1a) has one of the most wide-ranging tissues 
expression patterns, with the highest median (M= 10426.3), followed by Ubiquitin C 
(M=4620.6) and PGK1 (M=4.5).  One possible weakness of rEF1a is the low 
expression in heart and skeletal muscle tissues. However, given the near ubiquitous 
expression, we selected the rEF1a promoter for our Tg models. 
 
In our Tg models, GFP expression seems to be independent of integration site and 
genomic background and dependant of promoter endogenous/native activity. We 
visually confirmed that GFP expression follows the pattern of rEF1a mRNA 
expression, with a markedly lower expression in the heart, in both SHR and WKY 
rats, implying possibly that the rEF1a promoter is the main determinant in these 
strains of the level of tissue GFP expression. It would be interesting to perform 
further studies to quantify gfp mRNA versus rEF1a mRNA in tissues to assess 
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transcriptional correlation. If true, these models could be used as rEF1a expression 
reporter, and also as a rEF1a canonical function assay to deliver aa-tRNA to 
ribosome in mRNA translation. It could well be a reporter for cellular translation 
levels. The difference in GFP intensity between the SHR and WKY Tg models could 
be due to transgene copy, SHR with a single copy shows relatively lower expression 
of GFP than WKY with two integrations. Finally, heterogenous GFP expression 
within a tissue, such as the brain, may reflect differing chromatin state of the 
integration site. One hypothesis could be that, since the rEF1a promoter is essential 
in cellular protein translation, integration could make the chromatin more accessible 
in particular cell types if these loci are normally closed when translation occurs. 
Further work is needed to confirm whether these models reflect rEF1a expression in 
specific tissues and/or chromatin state after integration. 
 
In summary, we have created two novel Tg models expressing ubiquitous green 
fluorescent protein in WKY and SHR inbred rat lines to support in vivo and ex vivo 
studies in cell tracking, tissue and organ transplantation for further elucidation of the 
complex disease traits of human crescentic glomerulonephritis (CRGN) and 
metabolic syndrome respectively. Our preliminary study using real time imaging of 
kidney leukocyte-endothelial interactions in WKY-GFP bone marrow chimeras 
confirms the utility of GFP transgenic rats for fluorescent imaging. Both novel Tg 
lines have considerable value for future translational research in the scientific 
community. 
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Tables 
 
Table 1 Overall transgenesis efficiency by SB transposon system 
 
No of zygotes 
surviving microinjection 
and 
transferred to recipients. 
(Survival rate, %) 
No. of pregnant 
recipients (%) 
 
Efficiency of transposon 
integration (%) 
Per new born 
Per injected 
zygotes 
WKY-GFP 22/85 (25.8) 1/1 (100) 3/4 (75) 3/22 (13.6) 
SHR-GFP 96/270 (35.5) 3/3 (100) 6/8 (75) 6/96 (6.25) 
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Figures 
 
 
 
 
Figure 1. GFP transgenic rat design. (A) Schematic plasmid representation. rat 
Elongation Factor 1 alpha promoter (rEF1a) replaces CAG promoter (CAGGS).  IR = 
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Inverted repeats; GFP = Green Fluorescent Protein cDNA (GFP). (B) Photograph of 
WKY-GFP pups (left) and adult (right) rats under excitation light 489nm, showing 
wild type and GFP Tg animals. (C) Schematic genome locus showing TA integration 
sites location of T for SHR-GFP in chromosome 5, and WKY-GFP in chromosome 1 
and 8. Genomic sequence (left junction) in capitals and transgene in lowercase, 
dotted horizontal line refers to intergenic, continuous black line to intronic, and 
vertical blocks to exonic sequences. 
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Figure 2. GFP expression in embryos. Female WKT-GFP were crossed with 
wildtype WKY male rats and one-cell embryos removed and imaged under confocal 
microscope. Representation of 3 experiments from one-cell embryos at E4.5 and 
E4.5 plus 12hrs. Scale bar = 15μm top panel and 40μm bottom panel. 
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Figure 3. GFP expression in organs and tissues. Wild type (from SHR strain), 
WKY-GFP and SHR-GFP rats were examined for gross GFP expression in dissected 
heart, brain, kidney, eyes, thymus, gut, liver, spleen and muscle tissues. Whole 
organ extracts were mounted for stereo- fluorescent imaging. Scale bar = 2mm.  
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Figure 4. GFP expression in blood leukocyte populations. Anticoagulated blood 
from wildtype, WKY-GFP and SHR-GFP rats were examined for GFP expression 
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with or without fluorescent labelled antibodies using flow cytometry. (A).  Histograms 
of GFP expression in SSChi and SSClow populations. (B). Dot plots of GFP 
expression versus Gran, MHC-II or CD68 positive populations, gated from R1. 
Representative of at least n=4 rats.  
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Figure 5. GFP expression in BMDM and intravital microscopy. (A). Bone marrow 
derived macrophages (BMDM) were harvested and cultured for 5 or 10 days and 
intensity of GFP examined in WKY-GFP and SHR-GFP rats. Scale bar = 75μm. (B). 
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WKY rats underwent irradiation and BM transplant from WKY-GFP donor. After 
successful chimerisation, kidney cortex was imaged after injection of 70kDa 
fluorescent dextran under anaesthesia. Snapshot is shown of GFP positive cells 
interacting with endothelial surfaces within the kidney (arrows). Representative of at 
least n=4 rats. 
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